anti active β catenin (Cell Signaling Technology Inc)
Structured Review

Anti Active β Catenin, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 94/100, based on 35 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/src%2C+active/PathScan+Phospho-Src+(Tyr416)+Sandwich+ELISA+Antibody+Pair/pmc12973582-122-31-33
Average 94 stars, based on 35 article reviews
Images
1) Product Images from "ISX9 activates the Wnt/β-catenin signaling pathway and exerts neuroprotective effects in Alzheimer’s disease"
Article Title: ISX9 activates the Wnt/β-catenin signaling pathway and exerts neuroprotective effects in Alzheimer’s disease
Journal: Alzheimer's Research & Therapy
doi: 10.1186/s13195-026-01961-5
Figure Legend Snippet: ISX9 activates the Wnt/β-catenin signaling pathway in mouse hippocampal neuronal HT22 cells. ( A ) The SuperTOPFlash reporter gene was transfected into HT22 cells, and the cells were treated with solvent control (DMSO) and gradient concentrations of ISX9 (2.5-40 μM) for 24 h. Subsequently, the cells were lysed, and the fluorescence intensity was detected and normalized based on the value of the β-gal. ( B ) HT22 cells were treated with control and gradient concentrations of ISX9 (2.5-40 μM) for 24 h. The expression levels of endogenous β-catenin and activated β-catenin proteins were detected by Western blot. Quantitative analysis was performed by ImageJ and normalized relative to GAPDH values, and results were presented on the right. ( C ) HT22 cells were treated with control and 20 μM ISX9 for 24 h, respectively, followed by precipitation of cell lysates with an anti-AXIN1 antibody. The interaction of AXIN1 with LRP6 or β-catenin was detected by immunoblotting. ( D ) HT22 cells were treated with control or gradient concentrations of ISX9 (2.5-20 μM) for 24 h, respectively. After cell lysis, total RNA was extracted, and cDNA was obtained by reverse transcription. RT-qPCR was performed to detect the mRNA expression levels of Wnt target genes NOTUM, AXIN2 and SURVIVIN. The data shown are the mean ± SD (n = 3). Statistical significance was tested by one-way ANOVA followed by the Tukey test. * p < 0.05, ** p < 0.01, and *** p < 0.001 indicated that there was a significant difference compared with the control group
Techniques Used: Transfection, Solvent, Control, Fluorescence, Expressing, Western Blot, Lysis, Reverse Transcription, Quantitative RT-PCR
Figure Legend Snippet: ISX9 enhances the proliferation, and promotes the expression of stemness-related Wnt target genes in hippocampal neuronal cells. HT22 cells were treated with control or gradient concentrations of ISX9 for 24 h, respectively. The cell viability ( A ) and proliferation ( B ) of HT22 cells were detected by MTT and BrdU assays. ( C ) HT22 cells were treated with control or ISX9 (2.5-20 μM) for 24 h, respectively. The cells were lysed to extract total RNA, which was then subjected to reverse transcription for cDNA synthesis. RT-qPCR was performed to detect the mRNA expression levels of stemness-related Wnt target genes LGR5 and SOX2. ( D - F ) HT22 cells were treated with control and 20 μM of ISX9 for 24 h. Then the cells were fixed and followed by IF staining with DAPI and anti-β-catenin antibody ( D ) or anti-LGR5 antibody ( E ) or anti-SOX2 antibody ( F ). Alexa Fluor 594 conjugated goat anti-mouse IgG antibodies were used as secondary antibodies. Scale bar, 20 μm. The results of the quantitative fluorescence analysis were presented on the right. The data shown are the mean ± SD (n = 3). Statistical significance was tested by one-way ANOVA followed by the Tukey test. * p < 0.05, ** p < 0.01, and *** p < 0.001 indicated that there was a significant difference compared with the control group
Techniques Used: Expressing, Control, Reverse Transcription, cDNA Synthesis, Quantitative RT-PCR, Staining, Fluorescence
Figure Legend Snippet: ISX9 activates Wnt/β-catenin signaling in the hippocampus of AD mice. ( A ) Expression levels of total β-catenin and activated β-catenin protein in hippocampal tissues of WT, WT/ISX9, AD and AD/ISX9 group mice. The below bars show the results of quantification of the immunoblotting images by ImageJ and normalization relative to GAPDH values. ( B ) Protein was extracted from the hippocampal tissues of mice, followed by precipitation with an anti-AXIN1 antibody. The interaction of AXIN1 with LRP6 or β-catenin was detected by immunoblotting. ( C ) Total RNA extracted from mouse hippocampal tissues of mice was reverse transcribed to obtain cDNA, and then RT-qPCR was performed to detect the mRNA expression levels of Wnt target genes NOTUM, AXIN2 and SURVIVIN
Techniques Used: Expressing, Western Blot, Reverse Transcription, Quantitative RT-PCR
Related Articles
Nucleic Acid Electrophoresis:Article Title: ISX9 activates the Wnt/β-catenin signaling pathway and exerts neuroprotective effects in Alzheimer’s disease Article Snippet: The protein concentrations were determined using a bicinchoninic acid (BCA) protein assay kit (Beyotime). .. Equal amounts of proteins were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to polyvinylidene difluoride (PVDF) membranes for immunoblotting with the following antibodies: anti-β-catenin (Santa Cruz Biotechnology, Cat#sc-7963), Western Blot:Article Title: ISX9 activates the Wnt/β-catenin signaling pathway and exerts neuroprotective effects in Alzheimer’s disease Article Snippet: The protein concentrations were determined using a bicinchoninic acid (BCA) protein assay kit (Beyotime). .. Equal amounts of proteins were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to polyvinylidene difluoride (PVDF) membranes for immunoblotting with the following antibodies: anti-β-catenin (Santa Cruz Biotechnology, Cat#sc-7963), Article Title: The Aurora B inhibitor ZM-447439 induces caspase-independent necrosis-like death in v-Src oncogene-expressing cells via accumulation of extra-lysosomal cathepsin B. Article Snippet: Src signaling is aberrantly activated in various cancers, and therapeutic strategies targeting Src-dependent cancers have been developed.. We previously reported that cells expressing the oncogenic mutant v-Src are resistant to microtubule-targeting agents (MTAs), yet paradoxically exhibiting sensitivity to the Aurora B inhibitor ZM-447439; however, the mechanism underlying this cytotoxicity remains unclear.. In this study, we demonstrate that the Aurora B inhibitor ZM-447439 potentiates cell death in v-Src-expressing HeLa S3 and HCT116 cells, accompanied by the accumulation of tetraploid and polyploid cells. Article Title: v-Src delocalizes Aurora B by suppressing Aurora B kinase activity during monopolar cytokinesis. Article Snippet: c-Src tyrosine kinase plays roles in a wide range of signaling events and its increased activity is frequently observed in a variety of epithelial and non-epithelial cancers. v-Src, an oncogene first identified in the Rous sarcoma virus, is an oncogenic version of c-Src and has constitutively active tyrosine kinase activity.. We previously showed that v-Src induces Aurora B delocalization, resulting in cytokinesis failure and binucleated cell formation.. In the present study, we explored the mechanism underlying v-Src-induced Aurora B delocalization. Article Title: Disruption of ZNF334 promotes triple-negative breast carcinoma malignancy through the SFRP1/ Wnt/β-catenin signaling axis Article Snippet: .. Primary antibodies used in western blotting were listed as follows: ZNF334 (HPA050022; Sigma-Aldrich), β-actin (sc-8432; Santa Cruz), Immunofluorescence:Article Title: The Aurora B inhibitor ZM-447439 induces caspase-independent necrosis-like death in v-Src oncogene-expressing cells via accumulation of extra-lysosomal cathepsin B. Article Snippet: Src signaling is aberrantly activated in various cancers, and therapeutic strategies targeting Src-dependent cancers have been developed.. We previously reported that cells expressing the oncogenic mutant v-Src are resistant to microtubule-targeting agents (MTAs), yet paradoxically exhibiting sensitivity to the Aurora B inhibitor ZM-447439; however, the mechanism underlying this cytotoxicity remains unclear.. In this study, we demonstrate that the Aurora B inhibitor ZM-447439 potentiates cell death in v-Src-expressing HeLa S3 and HCT116 cells, accompanied by the accumulation of tetraploid and polyploid cells. Article Title: v-Src delocalizes Aurora B by suppressing Aurora B kinase activity during monopolar cytokinesis. Article Snippet: c-Src tyrosine kinase plays roles in a wide range of signaling events and its increased activity is frequently observed in a variety of epithelial and non-epithelial cancers. v-Src, an oncogene first identified in the Rous sarcoma virus, is an oncogenic version of c-Src and has constitutively active tyrosine kinase activity.. We previously showed that v-Src induces Aurora B delocalization, resulting in cytokinesis failure and binucleated cell formation.. In the present study, we explored the mechanism underlying v-Src-induced Aurora B delocalization. Flow Cytometry:Article Title: The Aurora B inhibitor ZM-447439 induces caspase-independent necrosis-like death in v-Src oncogene-expressing cells via accumulation of extra-lysosomal cathepsin B. Article Snippet: Src signaling is aberrantly activated in various cancers, and therapeutic strategies targeting Src-dependent cancers have been developed.. We previously reported that cells expressing the oncogenic mutant v-Src are resistant to microtubule-targeting agents (MTAs), yet paradoxically exhibiting sensitivity to the Aurora B inhibitor ZM-447439; however, the mechanism underlying this cytotoxicity remains unclear.. In this study, we demonstrate that the Aurora B inhibitor ZM-447439 potentiates cell death in v-Src-expressing HeLa S3 and HCT116 cells, accompanied by the accumulation of tetraploid and polyploid cells. Staining:Article Title: v-Src delocalizes Aurora B by suppressing Aurora B kinase activity during monopolar cytokinesis. Article Snippet: c-Src tyrosine kinase plays roles in a wide range of signaling events and its increased activity is frequently observed in a variety of epithelial and non-epithelial cancers. v-Src, an oncogene first identified in the Rous sarcoma virus, is an oncogenic version of c-Src and has constitutively active tyrosine kinase activity.. We previously showed that v-Src induces Aurora B delocalization, resulting in cytokinesis failure and binucleated cell formation.. In the present study, we explored the mechanism underlying v-Src-induced Aurora B delocalization. |

